17 results about "Lipocalin" patented technology

The present invention relates to recombinant C. acnes and method of producing thereof. The present invention provides a human neutrophil gelatinase-associated lipocalin (NGAL) protein derived from a recombinant bacterium and its uses thereof. Particularly, the present invention relates to the use of NGAL protein obtained from a recombinant bacterium in the treatment of acne vulgaris or as a cosmetical composition. Provided herein are also recombinant bacterium expressing NGAL protein and their uses.

The invention provides a method of detecting renal cancer mark- ers in a biological sample from a patient suspected of or to be evaluated for having renal cancer, comprising detecting one or more marker proteins selected from Lipocalin 15, Serum amyloid A1, and Haptoglobin, in the biological sample. The invention further provides a kit suitable for use with the inventive method.

The present invention discloses the use of tazemetostat in the preparation of drugs for treating acute kidney injury, and belongs to the field of biomedicine technology. Specifically, it also relates to the use of tazemetostat in the preparation of drugs for reducing the mRNA expression levels of lipocalin Ngal, kidney injury factor KIM1, chemokine MCP-1, inflammatory factors IL-1β, IL-6, and TNF-α, and the use of tazemetostat in the preparation of drugs for reducing the levels of creatinine and urea nitrogen in serum. Beneficial effect: The present invention proposes a new drug use of tazemetostat in the treatment of acute kidney injury. It effectively reduces the inflammatory response and renal damage level caused in an in vitro model of acute kidney injury; it can also reduce the expression levels of inflammatory factors IL-6 and chemokine MCP-1 in the serum of an in vivo animal model of renal injury, improve the kidney tissue pathology of animals with acute kidney injury, inhibit the protein expression of KIM1 in kidney tissue, reduce the levels of creatinine and urea nitrogen in kidney tissue serum, and has a potential therapeutic effect on acute kidney injury.

The invention provides an application of lurasidone or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and / or treating diabetes individual bone injury healing disorder. The hyperglycemia environment causes excessive secretion of lipocalin-2 (LCN2) by activating a phosphopentose pathway of neutrophil, thereby inhibiting osteogenic differentiation of skeletal stem cells. According to the application of the lurasidone or the pharmaceutically acceptable salt thereof in the preparation of the medicine for preventing and / or treating the diabetic individual bone injury healing disorder, in the application provided by the invention, the lurasidone can specifically inhibit the metabolic pathway and the secretion of LCN2, remodel an immune microenvironment beneficial to repair, and promote the healing of the diabetic individual bone injury. The formation of callus under the condition of diabetes mellitus is obviously accelerated and the mineral density of bone is improved.

The application provides preparation and application of a diagnostic monoclonal antibody for a new epitope of human neutrophil lipocalin (HNL). Two new HNL protein conformation epitopes and one new HNL linear epitope are designed and provided, and an anti-HNL antibody with higher binding affinity and better binding specificity is screened to combine the new epitopes. The anti-HNL antibody of the application can be used for preparation of an HNL detection reagent and kit, and has higher sensitivity and specificity when used for detecting HNL protein in a sample, and can be applied to distinguishing bacterial infection and viral infection.

The present invention relates to a neutrophil gelatinase-related lipid carrier antibody and its preparation method and application. Including: (1) constructing recombinant neutrophil gelatinase-associated lipid carrier antigen; (2) obtaining neutrophil gelatinase-associated lipid carrier antigen monomers and dimers; (3) mouse immunity; (4) constructing a single-chain antibody library for phages; (5) enrichment and screening. The invention uses antibody genetic engineering technology and phage display technology to construct a single-chain antibody library of phages, and screens out the ScFv of neutrophil gelatinase-related lipid carrier antibodies. It has high specificity and sensitivity and can specifically recognize neutrophil gelatinase-related lipid carrier antibodies. It is suitable for immunological detection, especially immunohistochemical detection, and provides a theoretical basis and material basis for the later establishment of rapid immunological detection of neutrophil gelatinase-related lipid carrier antibodies.

The present invention relates to recombinant C. acnes and methods for its production. The present invention provides a recombinant bacterially derived human neutrophil gelatinase-associated lipocalin (NGAL) protein and uses thereof. In particular, the present invention relates to the use of NGAL protein obtained from recombinant bacteria in the treatment of acne vulgaris or as a cosmetic composition. Also provided herein are recombinant bacteria expressing NGAL protein and uses thereof.

This invention relates to the field of bioengineering technology, specifically to a method for preparing neutrophil gelatinase-associated lipid transport protein and its antibody. Specifically, using pET23a(+) as the expression vector, the NGAL gene with six His tags fused to its N-terminus under promoter control is introduced into *E. coli* for induced expression. After purification using a Ni Focurose 6FF column and a molecular sieve column, tag-free NGAL protein with a purity ≥95% is obtained. Subsequently, the NGAL protein is used to repeatedly immunize Japanese rabbits, and serum is collected after each immunization. Qualified serum is screened using a two-dimensional agar diffusion assay, and then purified using the aforementioned antigen to prepare an antigen affinity purification column, yielding a highly active NGAL polyclonal antibody. The high-purity recombinant NGAL of this invention not only possesses activity but is also low-cost, not limited by raw materials, and can be mass-produced, possessing potential and wide-ranging application value in clinical and in vitro diagnostics.

The application belongs to the technical field of protein detection, and particularly relates to a protein marker detection platform based on a DNA nanoflower cascade CRISPR system and a construction method and application thereof. The protein marker detection platform based on the DNA nanoflower cascade CRISPR system comprises an upstream module of protein marker input signal amplification based on a DNA nanoflower and a downstream module of output signal amplification based on a CRISPR / Cas system. When the detection platform is used for protein marker detection, the upstream module based on the DNA nanoflower can convert the protein marker into hundreds or thousands of DNA signals, the DNA signals are recognized and activated by a Cas-crRNA compound to have Cas protein cis and trans cleavage activity, so that the output signal is amplified, high sensitivity and rapid detection of the protein marker are achieved, and in particular in detection of a neutrophil gelatinase lipocalin marker in a kidney injury disease, the detection limit is 500 fg / ml.

A method of reducing the risk of a sepsis-induced vascular leak, tissue edema or organ dysfunction is provided. The method involves administering an effective amount of a composition selected from the group consisting of Lipocalin 10 (SEQ ID NO: 1), a truncated Lipocalin 10 (Lcn10) protein having the amino acid sequence SEQ ID NO: 2, Lcn 10-expressing vectors for full length / truncated Lcn10, or combinations thereof to the subject, The method is also useful for reducing the risk of a heart attack-induced cardiac dysfunction, atherosclerosis, inflammatory bowel disease or diabetes-induced cardiomyopathy.

The present disclosure relates to a method for detecting the presence or absence of homodimer human neutrophil lipocalin (HNL) in a sample. Methods, kits, and devices for establishing the presence of or excluding a bacterial infection are also provided. The present invention allows for accurate and reliable detection of bacterial infections and monitoring of bacterial infections as well as monitoring of the efficacy of antibacterial treatments by specifically detecting homodimers HNL using a specific combination of specific monoclonal antibodies.

The present disclosure provides evidence that LCN2 is abundant in IBC cells. and that LCN2 silencing decreases cell proliferation, cell migration, and reduces the invasiveness ability of IBC cells. In vitro targeting of LCN2 with small molecule inhibitors suggests the potential of LCN2 as a plausible target for IBC treatment. Together, these findings support a novel targeted therapeutic approach for an aggressive and deadly invasive cancer, such as IBC.

The invention discloses a biomarker composition and application thereof, and belongs to the field of biomarker analysis and detection. The invention firstly provides a group of biomarker compositions, wherein the biomarker compositions comprise a Klotho protein and a neutrophil gelatinase associated lipocalin (NGAL); the combined detection biomarker composition can be used for early assessment of the risk of hypertensive disorder in pregnancy complicated with acute kidney injury. When the marker composition is used for predicting the risk of hypertensive disorder in pregnancy complicated with acute kidney injury, the risk of acute kidney injury can be recognized in advance in the early pregnancy stage.

The application belongs to the technical field of biological pigment reconstruction and protein engineering, and particularly relates to a pigment complex based on recombinant macrobrachium rosenbergii lipid carrier protein as well as an in-vitro preparation method and application thereof. The formation of the pigment complex relies on the synergistic stabilization of a key residue network of the recombinant macrobrachium rosenbergii lipid carrier protein, a pigment characteristic end group and phosphatidyl ethanolamine. The application has important scientific significance and industrial value for revealing the protein-pigment-lipid ternary interaction rule, constructing a thermal response color-changing system, expanding the application of protein-based pigment materials and providing a technical basis for color biomimetic construction in food and other systems.

The invention provides preparation and application of a monoclonal antibody for diagnosis aiming at a human neutrophil lipocalin (HNL) neoepitope. Two new HNL protein conformational epitopes and a new HNL linear epitope are designed and provided, and the anti-HNL antibody which is combined with the new epitopes and has higher binding affinity and better binding specificity is obtained through screening. The anti-HNL antibody disclosed by the invention can be used for preparing an HNL detection reagent and a kit, has higher sensitivity and specificity when being used for detecting HNL protein in a sample, and can be applied to distinguishing bacterial infection and virus infection.

The invention discloses a CNN-LSTM multi-feature fusion-based lipocalin classification method, which comprises the following steps: S1, constructing a data set, and dividing the data set into training data, verification data and test data; s2, extracting protein sequence features by using three feature descriptors of K-mer, CKSAAP and CC-PSSM, and fusing the protein sequence features through a feature integration technology; s3, performing dimensionality reduction optimization on the fused features by using principal component analysis (PCA), and reserving features with a variance proportion threshold value of 0.98 to obtain low-dimensional important features; s4, the features subjected to dimension reduction are input into a CNN-LSTM fusion model, CNN comprises 128 filters, the size of a convolution kernel is 1, an activation function is ReLU, LSTM comprises 64 units, and a category probability is output through combination of a full connection layer and a Softmax function; and S5, performing classification prediction on the lipid protein according to the output probability value. According to the method, the problems of insufficient characteristic utilization and high calculation cost of a traditional method are solved, and an efficient tool is provided for lipid protein function research and disease diagnosis.

The invention discloses application of tazeostat in preparation of a medicine for treating acute kidney injury, and belongs to the technical field of biological medicine. The invention specifically relates to application of the tazeostat in preparation of drugs for reducing mRNA expression levels of lipocalin Ngal, a kidney injury factor KIM1, a chemotactic factor MCP-1, inflammatory factors IL-1beta, IL-6 and TNF-alpha, and application of the tazeostat in preparation of drugs for reducing levels of creatinine and urea nitrogen in serum. The invention has the beneficial effect that the invention provides a new medicinal application of the tazeostat in treating the acute kidney injury. The inflammatory response and the renal injury level caused in an acute renal injury in-vitro model are effectively reduced; in addition, the pharmaceutical composition can also reduce the expression level of inflammatory factors IL-6 and chemotactic factors MCP-1 in serum of a kidney injury in-vivo animal model, improve kidney tissue pathology of acute kidney injury animals, inhibit protein expression of KIM1 in kidney tissues and reduce the levels of creatinine and urea nitrogen in serum of the kidney tissues, and has a potential treatment effect on acute kidney injury.